MoonLake Immunotherapeutics
MLTX
45 hedge funds and large institutions have $113M invested in MoonLake Immunotherapeutics in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 12 closing their positions.
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
5% more funds holding
Funds holding: 43 → 45 (+2)
1.73% more ownership
Funds ownership: 94.04% → 95.77% (+1.7%)
2% more capital invested
Capital invested by funds: $111M → $113M (+$1.75M)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.9M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$5.3M |
| 3 |
6CM
683 Capital Management
New York
|
+$4.37M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.69M |
| 5 |
AWG
Alpha Wave Global
New York
|
+$3.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$7.39M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$6.96M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$4.94M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.78M |
| 5 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$3.77M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCLSI
51
Bain Capital Life Sciences Investors
Boston,
Massachusetts
| – | -$2.49M | -250,000 | Closed |
|
|
FCMV
52
Foresite Capital Management V
Larkspur,
California
| – | -$2.49M | -250,000 | Closed |
|
|
RSCM
53
Rock Springs Capital Management
Baltimore,
Maryland
| – | -$1.54M | -154,500 | Closed |
|
|
CAC
54
Cowen and Company
New York
| – | -$622K | -62,475 | Closed |
|
|
GCL
55
Glazer Capital LLC
New York
| – | -$577K | -58,541 | Closed |
|
|
EAM
56
Exos Asset Management
New York
| – | -$250K | -25,100 | Closed |
|
57
Janus Henderson Group
London,
United Kingdom
| – | -$150K | -15,168 | Closed |
|
MLTX Hedge Fund Activity: Q4 2021 in Review
45 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q4 2021, worth a combined $113M — up 1.6% from $111M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new MLTX positions and 12 closed out — a net gain of 2 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $11.9M. The largest seller was RTW Investments, exiting entirely with an estimated $7.39M sold.
- 45 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q4 2021, up from 43 in Q3 2021.
- Funds reported $113M of MoonLake Immunotherapeutics stock for Q4 2021, up 1.6% quarter-over-quarter.
- 14 funds opened new MoonLake Immunotherapeutics positions in Q4 2021 and 12 closed out, a net change of +2 holders.
- The largest MoonLake Immunotherapeutics buyer in Q4 2021 was Fidelity Investments, an estimated $11.9M added.
- The largest MoonLake Immunotherapeutics seller in Q4 2021 was RTW Investments, an estimated $7.39M sold.
Based on aggregated 13F filings for Q4 2021.